Compare HubSpot Inc (HUBS) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Philip Morris International Inc. — how do they compare? HubSpot Inc trades at $232 (market cap $11.56B), while Philip Morris International Inc. trades at $199.94 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 27× HubSpot Inc's market cap, and Philip Morris International Inc. pays a 3.19% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Philip Morris International Inc. for 85 Days on average.
| HUBS | PM | |
|---|---|---|
Market Cap | $11.56B | $312.50B |
Volume | 1,891,287 | 5,517,172 |
Sector | Technology | Consumer Staples |
52-Week High | $494.58 | $200.50 |
52-Week Low | $170.39 | $144.33 |
Typical Hold Time | 78 Days | 85 Days |
Enterprise Value | $10.46B | $355.62B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $220.31, up 1.55% on the day, with a bearish technical signal but strong fundamental momentum. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth is robust, rising from $1.7B in 2022 to $3.1B in 2025, while net income turned positive in 2024. Recent news highlights an AI-focused strategy unveiled at Analyst Day and a deepened partnership with OpenAI, targeting margin expansion and SMB growth.
The outlook is cautiously optimistic, with a consensus price target of $243.65 implying ~11% upside. Key opportunities include sustained revenue growth, margin improvement, and AI integration, but risks involve high valuation multiples (P/E 78.39), competitive pressures, and insider selling. Wall Street sentiment is bullish (57% buy ratings), though technical indicators suggest near-term resistance.
Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.
Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
